Time-Line - Last Updated 1/28/19
4/28/17 – After months of back pain, (which started in February) followed by a CT, MRI and PET scans in April metastatic disease was confirmed! The metastatic disease has spread to basically all the bones in my body, most extensively within the spine/back. There is also extensive lymph node involvement across my chest.
5/3/17 - Lymph node biopsy at the collarbone confirmed ER/PR+ HER2- breast cancer.
Current treatment plans - Conventional:
Radiation: as needed for pain management: Bilateral hip/pelvis (lower lumbar) 10 rounds May-June 2017; T11, T12 & T13 (which has extensive cancer involvement) 10 rounds June 2017; humerus bone on left arm 10 rounds Oct 2017.
Chemo - Plan A: Ibrance (Palbociclib) which is a pill form of chemo. 21 days cycle followed by 7 days off. Plus Hormone Therapy: Letrozole. Tried Ibrance 125mg, 100mg & 75mg - Stopped treatment in September 2017.
Chemo - Plan B: Xeloda (Capecitabine) started with 1,500mg twice a day for 14 days followed by 7 days off, started in October 2017
Chemo - Plan C: IV Carboplatin once a week for 21 days followed by 7 days off, started in December 2017
Chemo - Plan D (includes plan c): IV Carboplatin once a week for 2 weeks followed by 14 days (2 weeks) off, started in December 2017 PLUS Lynparza (olaparib) chemo pill starting with 150 mg twice a day for 7 days (during the 1st week of Carboplatin) followed by 21 days off, started in January 2018
Chemo - Plan E: Eribulin once a week for 2 weeks followed by 1 week off, started November 2018, stopped January 2019.
PET Scans: 5/9/18 - Radiation "Speak" scan demonstrates decreased metabolic activity of adenopathy within the chest and abdomen compared to prior exam compatible with treatment effect with residual disease present. Trace residual righ pleural effusion with unchanged hyper-metabolic plural metastases. Overall decrease in metabolic activity of extensive osseous metastasis in the axial and appendicular skeleton compatible with treatment effect with residual disease present. Hypermetabolic activity in the marrow cavity of the bilateral humeri and femurs may be compatible with metastatic disease or marrow stimulation related to treatment.
PET Scans: 10/31/18 - Radiation "Speak" demonstrates innumerable FDG avid osseous lesions notably involving the spine, pelvis and proximal femoral bones, FDG avid right middle lobe nodular/consolidative opacity, multiple FDG avid right internal mammary/anterior mediastinal pleural-based nodules, possible left retrocrural lymph node, possible small left posterior chest wall FDG avid soft tissue focus, and few FDG avid left cervical lymph nodes. Findings compatible with worsening metastatic disease.
Current treatment plans - Alternative (homeopathic):
My Johns Hopkins Team
John Fetting - Medical Oncologist
Asrari Fariba - Radiation Oncologist
Majid Aziz Khan - Non Vascular Spine Intervention
No comments:
Post a Comment